Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mirati Therapeutics, Inc.

Latest From Mirati Therapeutics, Inc.

BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval

Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).

Approvals Launches

The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger

M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.

M & A Outlook 2024

Success For Mirati As EMA Backs Krazati For EU Approval After Initial Rejection

The European Medicines Agency has recommended the conditional approval of Mirati’s lung cancer drug Krazati following a re-examination of its initial negative opinion.

BioPharmaceutical Europe

EMA Says Yes To GSK’s Omjjara, UCB’s Rystiggo and Novartis’ Spexotras

Three orphan drugs were among the eight products recommended for pan-EU marketing approval by the European Medicines Agency this week, while Novartis withdrew its filing for Vijoice.

BioPharmaceutical Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • MethylGene Inc.